Selective proteasome inhibitors : modulators of antigen presentation?

Cite This

Files in this item

Files Size Format View

There are no files associated with this item.

GRÖTTRUP, Marcus, Gunter SCHMIDTKE, 1999. Selective proteasome inhibitors : modulators of antigen presentation?. In: Drug Discovery Today. 4(2), pp. 63-71. ISSN 1359-6446. eISSN 1878-5832. Available under: doi: 10.1016/S1359-6446(98)01292-6

@article{Grottrup1999Selec-22238, title={Selective proteasome inhibitors : modulators of antigen presentation?}, year={1999}, doi={10.1016/S1359-6446(98)01292-6}, number={2}, volume={4}, issn={1359-6446}, journal={Drug Discovery Today}, pages={63--71}, author={Gröttrup, Marcus and Schmidtke, Gunter} }

<rdf:RDF xmlns:dcterms="" xmlns:dc="" xmlns:rdf="" xmlns:bibo="" xmlns:dspace="" xmlns:foaf="" xmlns:void="" xmlns:xsd="" > <rdf:Description rdf:about=""> <dcterms:title>Selective proteasome inhibitors : modulators of antigen presentation?</dcterms:title> <dc:date rdf:datatype="">2013-03-27T13:34:18Z</dc:date> <dcterms:rights rdf:resource=""/> <dc:contributor>Schmidtke, Gunter</dc:contributor> <bibo:uri rdf:resource=""/> <foaf:homepage rdf:resource="http://localhost:8080/jspui"/> <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/> <dc:creator>Schmidtke, Gunter</dc:creator> <dcterms:isPartOf rdf:resource=""/> <dcterms:bibliographicCitation>Drug Discovery Today ; 4 (1999), 2. - S. 63-71</dcterms:bibliographicCitation> <dc:contributor>Gröttrup, Marcus</dc:contributor> <dspace:isPartOfCollection rdf:resource=""/> <dc:rights>terms-of-use</dc:rights> <dcterms:issued>1999</dcterms:issued> <dc:creator>Gröttrup, Marcus</dc:creator> <dcterms:available rdf:datatype="">2013-03-27T13:34:18Z</dcterms:available> <dcterms:abstract xml:lang="eng">The proteasome is the main nonlysosomal endoprotease in the cytoplasm and nucleus of all eukaryotic cells. It is responsible for the generation of most antigenic peptides as ligands for major histocompatibility complex (MHC) class I proteins. The proteasome hence qualifies as a target for modifying or silencing antigen processing and presentation to cytotoxic T cells, which are important players in transplant rejection and autoimmune disease. The authors summarize recent progress in the understanding of antigen processing by the proteasome and discuss the potential of novel and selective proteasome inhibitors as drugs for suppressing or modifying the cytotoxic immune response.</dcterms:abstract> <dc:language>eng</dc:language> </rdf:Description> </rdf:RDF>

This item appears in the following Collection(s)

Search KOPS


My Account